Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. has a filing covering a planned sale of up to 2,970 shares of common stock through Raymond James & Associates on or after 08/06/2026 on NASDAQ. The shares derive from cashless stock option exercises dated 04/27/2018 for 1,970 shares and 05/03/2019 for 1,000 shares. The Securities Information section also lists a related figure of 1,193,940.00 alongside the 2,970 shares.
Amgen Inc. insider(s) filed to sell common stock under Rule 144. The planned sales relate to shares acquired through cashless stock option exercises dated April 27, 2018 and May 3, 2019. Proposed sales for cash are expected on or after August 6, 2026, with the stock listed on NASDAQ and Raymond James & Associates involved as broker.
Amgen reported higher results for the quarter ended June 30, 2026, with total revenues of $10,054 million versus $9,179 million a year earlier and net income of $2,375 million versus $1,432 million. Diluted EPS was $4.37 compared with $2.65.
Large revenue contributors included Repatha, Prolia, EVENITY, TEPEZZA, BLINCYTO, Nplate, TEZSPIRE, XGEVA, KRYSTEXXA, KYPROLIS, Vectibix, UPLIZNA and IMDELLTRA/IMDYLLTRA. For the first six months, net cash provided by operating activities was $6,191 million, and cash and cash equivalents were $13,989 million, alongside $4.0 billion of new long-term debt issued in the first quarter.
Intangible assets totaled $20,487 million, including TAVNEOS developed-product-technology rights with a $2.4 billion carrying value; the FDA has proposed withdrawing TAVNEOS approval, and Amgen concluded the asset remained recoverable at June 30, 2026. The company is also managing IRA-driven U.S. pricing changes, significant IRS tax disputes and broader macroeconomic and geopolitical pressures.
Amgen Inc. reported second-quarter 2026 results with total revenues up 10% to $10.1 billion and total product sales up 9% to $9,537 million versus the second quarter of 2025. GAAP earnings per share rose 65% from $2.65 to $4.37, while non-GAAP EPS increased 4% from $6.02 to $6.29.
GAAP operating income grew from $2.7 billion to $3.5 billion, expanding GAAP operating margin by 6.5 percentage points to 36.8%. On a non-GAAP basis, operating income increased to $4.6 billion, with operating margin of 48.4%. Free cash flow was $3.5 billion in the quarter, compared with $1.9 billion a year earlier, supported by higher operating cash flow and the absence of a prior-year repatriation tax payment.
Growth was supported by medicines such as Repatha, EVENITY, TEZSPIRE, BLINCYTO and IMDELLTRA, while products including Prolia, Otezla, XGEVA and Enbrel saw lower volume or net selling prices amid biosimilar competition and U.S. pricing dynamics. Amgen ended June 30, 2026 with $14.0 billion in cash and cash equivalents and $57.3 billion of debt, and provided 2026 diluted EPS guidance of $15.80–$17.08 GAAP and $22.30–$23.50 non-GAAP.
Amgen Inc. reports a material cybersecurity incident involving unauthorized activity in data stored in cloud environments hosted by third-party providers. Some company data, including proprietary information, patient protected health information and other records, has been exfiltrated from those cloud systems.
Amgen activated its cybersecurity response plan, implemented containment measures and engaged independent forensic experts, and the investigation remains ongoing. The company has not identified any impact on its products, manufacturing operations, financial reporting systems or ability to meet patient needs, and currently believes the incident is not reasonably likely to have a material impact on its financial condition or results of operations. Amgen is assessing regulatory and legal notification obligations and plans to notify affected patients where required.
MILES AMY E reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Amy E. Miles received an equity award of 665 shares of common stock as a grant under the company’s director incentive program. The award, structured as Restricted Stock Units that vested immediately and settle one-for-one in common shares, increased her direct holdings to 5,640 shares. This total includes 408 dividend equivalents credited to her unvested RSUs under a qualifying dividend reinvestment plan.
Kullman Ellen Jamison reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Ellen Jamison Kullman received a grant of 665 shares of common stock as a stock-based award. The award was in the form of Restricted Stock Units (RSUs) under Amgen’s 2009 director incentive and equity incentive plans and vested immediately, with each vested RSU paid in one share of common stock rather than through an open-market purchase.
After this grant, Kullman directly holds a total of 14,535.9807 Amgen shares, which include 2,121 dividend equivalents (DEs) that are credited to her unvested RSUs and will be paid in shares as those RSUs vest, along with cash for any remaining fractional share amount.
Klotman Mary E. reported acquisition or exercise transactions in this Form 4 filing.
Amgen director Mary E. Klotman received an equity award of 665 shares of common stock in the form of Restricted Stock Units. The RSUs were granted under Amgen’s 2009 Director Incentive Program and vested immediately, paying out in common shares on a one-to-one basis.
Following this grant, Klotman directly holds 2,211 shares of Amgen common stock, which include 18 dividend-equivalent units credited to her unvested RSUs under the company’s equity incentive plan.
Jacks Tyler reported acquisition or exercise transactions in this Form 4 filing.
Amgen Inc. director Tyler Jacks reported a compensation-related equity grant rather than an open-market trade. He received 665 shares of common stock via immediately vesting Restricted Stock Units under Amgen’s 2009 Director Incentive Program. After this award, he directly holds 18,284 common shares, including 2,975 dividend equivalents tied to unvested RSUs that will be paid in stock as they vest.